Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Ovoca Bio. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Ovoca Bio's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ovoca Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Ovoca Bio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Ovoca Bio's earnings growth to the Ireland market average as no estimate data is available.
Unable to compare Ovoca Bio's revenue growth to the Ireland market average as no estimate data is available.
Unable to determine if Ovoca Bio is high growth as no earnings estimate data is available.
Unable to determine if Ovoca Bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Ovoca Bio's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Kirill Golovanov has been the Chief Executive Officer at Ovoca Gold plc since May 2012. Mr. Golovanov has been Corporate Secretary of Ovoca Gold plc since March 2010. Mr. Golovanov joined Ovoca as a corporate advisor in 2007 and moved to be the manager of its Russia representative office in 2009. During his time at Ovoca he played a major role in the development and subsequent sale of the Goltsovoye silver deposit. He has extensive experience in mining and corporate law, as well as working experience at leading Russian enterprises, such as Gazprombank and Vneshekonombank. Additionally, he was a department manager in the Federal Service on Bankruptcy and Finance Restoration - a subdivision of the Russian Federation Ministry of Finance. He serves as an Executive Director of Ovoca Gold plc. He served as a Non-Executive Director of Ovoca Gold plc since April 12, 2012. He has JD from Moscow State Legal Academy, Moscow Russia.
Kirill's compensation has been consistent with company performance over the past year, both up more than 20%.
Kirill's remuneration is higher than average for companies of similar size in Ireland.
CEO, Company Secretary & Executive Director
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Ovoca Bio board of directors is about average.
Does The Ovoca Bio plc (ISE:OVXA) Share Price Fall With The Market?
Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.
Could The Ovoca Bio plc (ISE:OVXA) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Ovoca Bio plc (ISE:OVXA) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Ovoca Bio is a smaller company with a market capitalization of €8.6m, so it may still be flying under the radar of many institutional investors.
Could The Ovoca Bio plc (ISE:OVXA) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Ovoca Bio plc (ISE:OVXA) can tell us which group is most powerful. … Generally speaking, as a company grows, institutions will increase their ownership. … Ovoca Bio is a smaller company with a market capitalization of €7m, so it may still be flying under the radar of many institutional investors.
Why Ovoca Gold plc's (ISE:OVXA) Ownership Structure Is Important
In this analysis, my focus will be on developing a perspective on Ovoca Gold plc’s (ISE:OVXA) latest ownership structure, a less discussed, but important factor. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … Check out our latest analysis for Ovoca Gold
How Should You Think About Ovoca Gold plc's (ISE:OVXA) Risks?
View our latest analysis for Ovoca Gold An interpretation of OVXA's beta Ovoca Gold's beta of 0.19 indicates that the stock value will be less variable compared to the whole stock market. … OVXA’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … How OVXA's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.
Breaking Down Ovoca Gold plc's (ISE:OVXA) Ownership Structure
In this article, I'm going to take a look at Ovoca Gold plc’s (ISE:OVXA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … See our latest analysis for Ovoca Gold ISE:OVXA Ownership_summary Mar 20th 18 Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.
Why Ovoca Gold plc's (ISE:OVXA) ROE Of 7.98% Does Not Tell The Whole Story
See our latest analysis for Ovoca Gold Breaking down ROE — the mother of all ratios Return on Equity (ROE) weighs Ovoca Gold’s profit against the level of its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Ovoca Gold’s equity capital deployed. … Given a discrepancy of -1.96% between return and cost, this indicated that Ovoca Gold may be paying more for its capital than what it’s generating in return.
Ovoca Bio plc focuses on development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing Libicore, a medication for treatment of female sexual dysfunction. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.